Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Stoke Therapeutics, Inc. (STOK)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results|
Docs:
|
"Stoke Therapeutics, Inc. Consolidated balance sheets June 30, December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 192,060 $ 113,556 Marketable securities 39,387 116,039 Prepaid expenses 10,950 10,932 Other current assets 3,699 2,955 Interest receivable 136 588 Total current assets $ 246,232 $ 244,070 Restricted cash 569 569 Operating lease right-of-use assets 3,646 4,753 Property and equipment, net 6,472 6,675 Total assets $ 256,919 $ 256,067 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 1,556 $ 766 Accrued and other current liabilities 12,222 15,748 Deferred revenue - current portion 8,059 14,880 Total current liabilities $ 21,837 $ 31,394 Deferred revenue - net of current portion 43,258 36,856 Other long term liabilities 1,629 2,968 T..." |
|
| 07/25/2023 |
8-K
| Quarterly results |
| 05/24/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/22/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 03/06/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/06/2023 |
8-K
| Quarterly results |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 7.7% stake in STOKE THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 4.1% stake in Stoke Therapeutics Inc. |
| 02/03/2023 |
SC 13G/A
| Redmile Group, LLC reports a 9.7% stake in Stoke therapeutics, Inc. |
| 02/03/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 01/25/2023 |
SC 13G/A
| Cowen Financial Products LLC reports a 1.9% stake in Stoke Therapeutics, Inc. |
| 01/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 12/02/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/08/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/20/2022 |
8-K
| Quarterly results |
| 05/20/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/10/2022 |
8-K
| Quarterly results |
|
|
|